Discover

TNXP
Tonix Pharmaceuticals Holding Corp.
12.44
2 x 11.51
1 x 13.00
bid
ask
-
0.32
2.51%
2 @ 07:12 AM
12.76 +0.32 (2.59%)
Ytd-20.36%
1y-64.63%
12.29
day range
12.97
10.03
52 week range
69.97
Open12.84Prev Close12.76Low12.29High12.97Mkt Cap198.30M
Vol287.50KAvg Vol485.44KEPS-14.66P/EN/AForward P/E-0.01
Beta2.08Short Ratio0.35Inst. Own0.23%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg12.73200-d Avg16.211yr Est5.83

TNXP News

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
globenewswire.com
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for th

HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluat

This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
benzinga.com
This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday
benzinga.com
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For

Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s

benzinga.com
Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Ta

Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with

Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA
benzinga.com
Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA

Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial paye

benzinga.com
Tonix Pharmaceuticals Enters Agreement With A Group Purchasing Organization To Provide Coverage For

Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides

benzinga.com
Tonix Pharma Presents Data From Real-World Claims Analysis Of Opioid Use In US Adults With Fibromyal

Real-world analysis of three years of closed claims data from Symphony Health, focused on the third

benzinga.com
Tonix Pharmaceuticals' TNX-1500 Shows Favorable Safety Profile In Phase 1 Study As Phase 2 Kidney Tr

Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-

benzinga.com
Tonix Pharmaceuticals' ISPOR 2026 Data Show 93.2% Comorbidity Burden And $29,896 Annual Inpatient Co

Real-world analysis of three years of closed claims data from Symphony Health focused on the third y

benzinga.com
Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the

Why Tonix Pharmaceuticals Shares Are Rallying Wednesday
benzinga.com
Why Tonix Pharmaceuticals Shares Are Rallying Wednesday

Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer

benzinga.com
Tonix Pharmaceuticals Announced An Agreement Effective May 1, 2026, With Group Purchasing Organizati

Agreement with leading group purchasing organization (GPO) provides access to approximately 35 milli

benzinga.com
TD Cowen Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $22

TD Cowen analyst Stacy Ku initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy ra

benzinga.com
Tonix Pharma Presents Phase 1 Data And Plans For Adaptive Phase 2 Field Study Of TNX-4800 For Preven

Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field

benzinga.com
Tonix Pharma Announces Oral Presentation And Two Poster Presentations On Preclinical Immuno-Oncology

TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significan

benzinga.com
Tonix Pharmaceuticals Announces Publication Of The Paper "Steady-State Pharmacokinetic Properties Of

The publication reports findings from a single-center, randomized, open-label, multiple-dose, parall

benzinga.com
Tonix Pharmaceuticals Says Phase 1 Data of TNX-4800 (mAb 2217LS) For Preventing Lyme Disease Demonst

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?
benzinga.com
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a

benzinga.com
Tonix Announces First Participant Dosed In Phase 1 Investigator-Initiated Study To Evaluate Effect O

Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models an

benzinga.com
Tonix Pharmaceuticals Presents Phase 1 Data On TNX-4800, Long-Acting Human mAb Targeting OspA Of Bor

Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch
benzinga.com
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch

Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptio

benzinga.com
Tonix Pharma Announces Two Oral Presentations On TONMYATM, Investigated As TNX-102 SL, At 8th Intern

Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In pos

benzinga.com
Tonix Pharmaceuticals Revealed Data On TONMYATM At The 2026 American Academy of Pain Medicine PainCo

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

benzinga.com
Tonix Pharmaceuticals Announces Publication Of Clinical Studies Of TONMYA In Medical Journal

TONMYA™ was investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets) and approved by the

Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting
benzinga.com
Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting

Tonix shares fell 2% premarket after the Nasdaq Global Select uplisting, with technical indicators s

benzinga.com
Tonix Pharmaceuticals Presents Data On TONMYA, Which Was Investigated As TNX-102 SL, At 2026 Non-Opi

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3

10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session

Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026
benzinga.com
Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026

TNXP announced updates on TNX-4800, a long-acting mAb targeting Lyme disease. Seeking FDA meeting in

benzinga.com
Tonix Sells 615,025 Shares at $16.26 Each in $20M Stock Deal With Point72

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

benzinga.com
Tonix Pharmaceuticals Announces Plans To Meet FDA In 2026 To Mull TNX-4800 Phase 2/3 Development Opt

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

benzinga.com
Tonix Pharma Announces Licensing Exclusive Worldwide Rights To TNX-4900, Small-Molecule S1R Antagoni

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemothera

benzinga.com
Tonix Pharma Announces FDA Clears IND Application To Support Clinical Development Of TNX-102 SL 5.6

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major d

Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning
benzinga.com
Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning

Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commerci

benzinga.com
Tonix Pharmaceuticals' TONMYATM Now Commercially Available Across U.S.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a ful

benzinga.com
Tonix Pharmaceuticals Q3 EPS $(3.59) Misses $(3.58) Estimate, Sales $3.290M Beat $3.100M Estimate

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(3.59) per share which missed the

benzinga.com
Tonix Teams Up With Mass General To Test New Antibody For Kidney Transplant Patients

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

benzinga.com
Tonix Pharma Presents Data On Tonmya, Which Was Investigated As TNX-102 SL, At 2025 ACR Convergence

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3

benzinga.com
Tonix Starts First Patient Dosing in Study Testing Oxytocin Therapy for Rare Disorder

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

benzinga.com
Tonix Pharmaceuticals CEO Highlights TNX-1500 Progress and Anti-CD154 Therapy in Organ Transplantati

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

benzinga.com
Tonix Pharma Plans To Progress TNX-2900 Program For Treatment Of PWS Into Phase 2 Clinical Trial

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children

benzinga.com
Tonix Pharmaceuticals Completes Type B Pre-IND Meeting With FDA For TNX-102 SL For Treatment Of Majo

Tonix anticipates filing the IND application in the fourth quarter of 2025TNX-102 SL is a potential

benzinga.com
Tonix Pharmaceuticals Announces In-Licensing Of TNX-4800 Monoclonal Antibody For Annual Lyme Disease

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: ef

benzinga.com
Tonix Presents Clinical Data On Tonmya For Treatment Of Fibromyalgia At PAINWEEK Conference 2025; Ph

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August
benzinga.com
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years
benzinga.com
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. l